Process development building opened
WACKER opened a process development building for the production of pharmaceutical proteins, or biologics, at the company's site in Jena, Germany. The new unit is reported to be capable of shipping double-digit gram quantities of highly pure proteins for pre-clinical development, prior to scale-up in the company's GMP plant.
WACKER opened a process development building for the production of pharmaceutical proteins, or biologics, at the company's site in Jena, Germany.
The new unit is reported to be capable of shipping double-digit gram quantities of highly pure proteins for pre-clinical development, prior to scale-up in the company's GMP plant. The infrastructure of the new building has been specifically designed to cater for the sophisticated process and analytics development necessitated by modern biologics based on microbial systems.
Aside from the actual process laboratories, the new unit boasts modern analytical laboratories for safeguarding the development of methods of process and product characterization right through to GMP analysis. These include a range of analytical tools, including biochemical assays, chromatography and electrophoresis. The unit also accommodates photometry, protein sequencing, spectroscopy and trace analysis of impurities, (DNA, HCP, endotoxins).
For further details, visit www.wacker.com/biologics
LC–MS/MS-Based System Used to Profile Ceramide Reactions to Diseases
April 26th 2024Scientists from the University of Córdoba in Córdoba, Spain recently used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to comprehensively profile human ceramides to determine their reactions to diseases.
High-Throughput 4D TIMS Method Accelerates Lipidomics Analysis
April 25th 2024Ultrahigh-pressure liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) had been previously proposed for untargeted lipidomics analysis, but this updated approach was reported by the authors to reduce run time to 4 min.
